(Q36122672)

12 August 2017

1 reference

title

The current role of chemotherapy in metastatic hormone-refractory prostate cancer (English)

1 reference

12 August 2017

1 reference

1 reference

Daniel P Petrylak

1

1 reference

PubMed ID

15885271

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

65

1 reference

12 August 2017

3-7; discussion 7-8

1 reference

12 August 2017

5 Suppl

1 reference

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for pr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.053

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2005.03.053

1 reference

12 August 2017

1 reference

PubMed ID

15885271